Skip to content
2000
Volume 25, Issue 39
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

The trypanosomatids, Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp, are causative agents of important human diseases such as African sleeping sickness, Chagas’ disease and Leishmaniasis, respectively. The high impact of these diseases on human health and economy worldwide, the unsatisfactory available chemotherapeutic options and the absence of human effective vaccines, strongly justifies the search for new drugs. The pentose phosphate pathway has been proposed to be a viable strategy to defeat several infectious diseases, including those from trypanosomatids, as it includes an oxidative branch, important in the maintenance of cell redox homeostasis, and a non-oxidative branch in which ribose 5-phosphate and erythrose 4-phosphate, precursors of nucleic acids and aromatic amino acids, are produced. This review provides an overview of the available chemotherapeutic options against these diseases and discusses the potential of genetically validated enzymes from the pentose phosphate pathway of trypanosomatids to be explored as potential drug targets.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867325666171206094752
2018-12-01
2025-06-24
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867325666171206094752
Loading

  • Article Type:
    Review Article
Keyword(s): drug targets; pentose phosphate pathway; treatment; Trypanosomatids
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test